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Hepatocellular Carcinoma in Hepatitis D: Does it Differ from 
Hepatitis B Monoinfection?
Zaigham Abbas, Mustafa Qureshi, Saeed Hamid, Wasim Jafri
ABSTRACT
Background/Aim: Hepatitis D virus (HDV) superinfection in patients with chronic hepatitis B leads to 
accelerated liver injury, early cirrhosis, and decompensation. It may be speculated that hepatocellular 
carcinoma (HCC) may differ in these patients from hepatitis B virus (HBV) monoinfection. The aim of 
this study was to compare clinical aspects of hepatocellular carcinoma in patients of hepatitis D with HBV 
monoinfection. Patients and Methods: A total of 92 consecutive HCC cases seropositive for antibody against 
HDV antigen (HDV group) were compared with 92 HBsAg-positive and anti-HDV-negative cases (HBV 
group). Results: The features including sex, body mass index, presence of ascites, serum biochemistry, 
gross tumor appearance, child class, barcelona cancer liver clinic and okuda stages were not significantly 
different between the 2 groups. Decreased liver size was noticed more in cases of HDV compared with HBV 
group where the liver size was normal or increased (P=0.000). HDV patients had lower platelets (P=0.053) 
and larger varices on endoscopy (P=0.004). Multifocal tumors and elevated alpha-fetoprotein level >1000 
IU/mL were more common in HBV group (P=0.040 and P= 0.061). TNM classification showed more stage 
III–IV disease in HBV group (P=0.000). Conclusion: Decreased liver size and indirect evidence of more 
severe portal hypertension and earlier TNM stage compared with HBV monoinfection indicate that HDV 
infection causes HCC in a different way, possibly indirectly by inducing inflammation and cirrhosis.
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Chronic hepatitis B is a major cause of cirrhosis, hepatocellular 
carcinoma (HCC), and liver-related mortality worldwide. 
Coinfection with hepatitis D virus (HDV) is associated 
with more severe liver disease and poor prognosis.[1-3] HDV 
is a defective RNA virus that requires hepatitis B virus 
(HBV) as helper virus.[4] Two viruses share the same route 
of transmission, being transmitted by contaminated blood 
and body fluids. HDV can infect simultaneously with HBV 
(coinfection) or in a patient with already established HBV 
infection (superinfection).
Although the incidence of HDV infection has decreased in the 
endemic countries as a result of effective immunoprophylaxis 
against HBV and improvement in socioeconomic and hygienic 
conditions,[5-7] it remains a relevant cause of morbidity in the 
Asia Pacific region.[8] There is no satisfactory treatment of 
hepatitis D. HDV infection is a critical problem in our country. It 
is present in 16.6% of hepatitis B–infected patients in Pakistan, 
most commonly in younger males living in rural areas.[9]
HDV infection increases the risk for HCC threefold 
and mortality twofold in patients with HBsAg-positive 
cirrhosis. [10] In a study from Japan the overall relative risk for 
liver cirrhosis and HCC was 2.58 and 2.87, respectively.[11] 
However, these findings were contradicted by a retrospective 
analysis of 962 HBV patients that showed similar rates 
of HCC in the 82 HDV-infected patients and 880 non-
infected patients.[12] According to another study, persistent 
HDV replication leads to cirrhosis and HCC at annual 
rates of 4% and 2.8%, respectively, and is the only predictor 
of liver-related mortality.[13] The aim of this study was to 
compare clinical features and tumor characteristics of HCC 
in hepatitis D antibody–positive patients with hepatitis B 
monoinfection in an Asian country with a high prevalence 
of HDV infection.
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PATIENTS AND METHODS
All adult patients (age ≥18 years) with HCC associated 
with chronic HDV infection who were admitted under 
Gastroenterology Hepatology Services in a tertiary care 
hospital between January 1999 and June 2009 were identified 
by ICD coding. These consecutive cases were reviewed and 
compared with consecutive HBV monoinfection-related 
HCC patients who were positive for HBsAg, but seronegative 
for HDV and managed during the same time period.
Due to high prevalence of hepatitis D, it is an institutional 
policy to rule out hepatitis D in every case of hepatitis B. 
HBV and HDV infections were diagnosed by commercially 
available enzyme-linked immunosorbent assays for HBsAg 
and anti-HDV antibody. Antibody to hepatitis C virus was 
assayed by a third-generation test system. Patients were 
labeled as suffering from HBV monoinfection if antibodies 
for both hepatitis C and D were found negative in a patient 
with reactive HBsAg. The diagnosis of HCC was defined as 
either the presence of a hepatic lesion >2cm in diameter 
on triphasic CT with typical vascular pattern for HCC 
(hypervascular with washout in the portal/venous phase) with 
or without elevated alpha-fetoprotein >200 ng/mL or the 
presence of a lesion1–2 cm in diameter with typical vascular 
pattern for HCC on two dynamic imaging techniques.[14]
Demographic data (age, sex, body mass index were 
extracted from patients’ records. Patients with cirrhosis 
were identified based on clinical features of cirrhosis and/
or radiologic evidence of cirrhosis in the context of portal 
hypertension (ascites, varices, thrombocytopenia, or hepatic 
encephalopathy). Patient data from the first clinic visit or 
admission with HCC were used to calculate Child–Turcotte–
Pugh score and stage of HCC by Okuda,[15] Barcelona Cancer 
Liver Clinic (BCLC),[16] and TNM staging systems.[17] Alpha-
fetoprotein levels during the same admission were also noted.
All of these patients underwent ultrasound examination 
followed by a triphasic CT scan.
Ultrasound examinations were carried out by experienced 
radiologists with the fasting subjects lying in the supine 
position. Measurement of the liver diameter was done in 
the right midclavicular line during deep inspiration. The 
size of the liver was measured from the hepatic dome to the 
inferior hepatic tip. The liver diameter of 12–15 cm was taken 
as normal.[18] Numbers of the tumor lesions were counted 
from the CT scan.
Endoscopic evaluation of varices was recorded where 
available. Endoscopy was performed by the same group of 
physicians. Grading system to document the size of varices 
being followed in our hospital evaluates varices as follows: 
Grade I, varices present but flatten completely with air 
insufflations; grade II, nonflatteningvarices that occupy 
10%–30% of the esophageal luminal radius; grade III, varices 
occupy 31%–60% of the esophageal luminal radius; grade 
IV, varices occupy 61%–100% of the esophageal luminal 
radius. [19,20] For this study Grade I–II varices were grouped 
together as small and Grade III–IV as large varices.
Statistical analysis
Descriptive statistics were computed for all variables. Chi-
square test was used for dichotomous variables and Mann–
Whitney U test for continuous variables. P value of less 
than 0.05 was taken as significant. SPSS version 17 software 
(SPSS, Chicago, IL, USA) was used for all analyses.
RESULTS
Total number of patients of HCC seropositive for HDV 
identified were 92 (HDV group). They were compared with 
92 consecutive HBsAg positive but anti-HDV negative 
HCC cases (HBV group). Combining two groups the study 
includes 184 patients, 84% of patients were males (male 155 
and females 29). Their age was 54.6 ± 11.1 years (median 
55, range 18–85). Most of these patients were in Child class 
B or C (A=26, B=76, C=82) with a median Child–Pugh 
score of 9 (5–14). Their Okuda stage was II in 106 (57.6%), 
III in 54 (29.4%), and I in 24 (13%).
The mean age was not different in both groups of patients 
(55.4 years in HDV group and 53.6 in HBV group). Other 
features, including sex, presence of ascites, serum biochemistry, 
and Child class, were not significantly different between the 
two groups [Table 1]. Decreased liver size was noticed more 
in cases of HDV compared with HBV group where the liver 
size was normal or increased (P=0.000). HDV patients had 
lower platelets (P=0.053). Endoscopic evaluation of varices 
was available in 77 patients, 39 in the HDV group and 38 in 
the HBV group. HDV group had more “large” (grade III–IV) 
varices on endoscopy compared with HBV group (P=0.004).
The mean alpha-fetoprotein levels were higher in HBV 
patients than in HDV patients (17612 vs 10215). However, 
there was no statistically significant difference. More patients 
in HBV group had elevated alpha-fetoprotein >1000; P value 
of 0.061 though not significant, did show a trend [Table 2]. 
Multifocal tumors were more common in HBV group 
(P=0.040). TNM classification showed more stage III–IV 
disease in HBV group (P=0.000),although there was no 
difference in Okuda or BCLC stage (P=0.764 and P=1.000).
DISCUSSION
HCC is a substantial complication of liver cirrhosis. It is 
recognized that HBV is one of the few human oncogenous 
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HBV has a direct oncogenic potential as well.[28] HBV 
DNA integrates into cellular DNA but is not an acutely 
transforming virus, because HCC usually develops decades 
after infection. Other factors, namely cirrhosis, inflammation, 
alcohol intake, and viral superinfections, could promote 
the oncogenetic process induced by HBV. HDV infection, 
superimposed on the oncogenetic background provided 
by chronic HBV infection appears to provide an additional 
promotion risk for HCC. Our HDV-positive patients had 
decreased liver size and indirect evidence of more severe 
portal hypertension and earlier TNM stage compared with 
HBV monoinfection, which may indicate that HDV infection 
causes HCC possibly indirectly by inducing inflammation 
and cirrhosis.
Patients with florid infections from both HBV and HDV and 
active liver inflammation should develop HCC at a younger 
age than those infected by HBV alone.[29,30]
However, there was no significant age difference in our study. 
This may be because in endemic areas HDV may superinfect 
at any age and start the aggressive disease leading to cirrhosis 
Table 1: Characteristics of patients with HBV and HDV 
hepatocellular carcinoma
HBV (n=92) HDV (n=92) P value
Age (years ± SD) 53.6 ± 11.3 55.4 ± 10.8 0.339
Sex
Male 75 80 0.312
Female 17 12
Body mass index (kg/m2) 23.9 ± 5.2 23.4 ± 5.4 0.452
Decreased liver size 23 49 0.000
Splenomegaly 46 52 0.375
Variceal size
Small/large 16/22 5/34 0.004
ALT (IU/L) 93.2 ± 101 99.2 ± 94.3 0.714
AST (IU/L) 215.3 ± 452 226.2 ± 454.6 0.684
Alkaline phosphatase (IU/L) 195.6 ± 123 187.5 ± 101.4 0.922
GGT (IU/L) 160.5 ± 144.4 137.7 ± 109.2 0.394
Platelets (×106/L) 169 ± 108 141 ± 86 0.053
Hemoglobin (g/dL) 11.6 ± 2.2 13.6 ± 19.1 0.945
INR 1.54 ± 0.54 1.61 ± 0.58 0.410
Serum albumin (g/dL) 2.45 ± 0.60 2.51 ± 1.15 0.535
Child class
A
B
C
12
43
37
14
33
45
0.325
Pugh score 9.4 ± 2.3 9.2 ± 2.4 0.724
ALT: Alanine aminotransferase, AST: Aspartate aminotransferase,  
GGT: Gamma-glutamyltranspeptidase, HBV: Hepatitis B virus, HDV: Hepatitis 
D virus
Table 2: Tumor characteristics of HBV and HDV 
hepatocellular carcinomas
HBV (n=92) HDV (n=92) P value
Number of lesions
Solitary
2–3
>3
23
39
30
36
31
25
0.120
Multifocal tumor 69 56 0.040
Size of biggest lesion (cm)
1–3
3.1–5
>5
27
19
46
26
19
47
0.985
Portal vein invasion or 
thrombosis
31 29 0.753
Alpha-fetoprotein
(IU/mL)
Mean±S.D.
Median
Range
>200
>1000
17612 ± 79474
208.0
1.57–730000
49
37
10215 ± 35563
114.0
0.83–300000
43
25
0.165
0.376
0.061
BCLC stage
A or B
C or D
21
21
71
71
1.000
Okuda stage
I
II
III
10
5725
14
49
29
0.457
TNM-based stage
I and II
III–IV
01
91
17
75
0.000
BCLC: Barcelona clinic liver cancer, HBV: Hepatitis B virus, HDV: Hepatitis  
D virus
viruses.[21] HCC incidence is higher in countries where 
hepatitis B is endemic. Addition of HDV infection seems 
to increase the risk of HCC development. HDV-related 
cirrhosis is usually an aggressive disease with a median time 
to decompensation less than 2 years and a median survival 
less than 5 years.[22] However, as with any immune-mediated 
disease, different patterns of progression, ranging from 
mild to severe progressive disease, are observed.[23] In these 
patients, it is the clinical decompensation and not HCC, 
which is the first dominant complication to appear. Severity 
of HDV infection may be an important predictor of HCC. 
Patients infected with genotype one HDV have a lower 
remission rate, more aggressive disease, and more adverse 
outcomes (cirrhosis, hepatocellular carcinoma, or mortality) 
than those with genotype II HDV.[24,25]
Unfortunately HDV genotype I is prevalent in our country 
and in one of our previous studies all the HDV patients 
belonged to this genotype.[26] HBV genotype D is prevalent in 
about 95% of our HBV patients.[27]Although the information 
about genotypes is not available in the present study, it may 
be presumed that most of our patients would be harboring 
HDV genotype I and HBV genotype D.
Hepatitis viruses may cause HCC through an indirect 
mechanism inducing inflammation and cirrhosis,whereas 
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and eventually HCC. It is also known that active replication 
of HBV promotes carcinogenesis[31] and HDV can inhibit 
HBV genome and replication[32,33] and could interfere with 
cancer development in HDV patients with less aggressive 
disease. This ability of HDV to suppress HBV replication 
could represent a protective mechanism to lower the risk of 
HCC development.
There was much difference in TNM-based staging among 
two groups. Our patients of hepatitis B were mostly in 
stage III–IV. This may reflect a more aggressive tumor 
behavior. This trend is also reflected by a higher number 
of HBV group patients having their alpha-fetoprotein level 
>1000 IU/mL. On the other hand, early stage in HDV HCC 
could be attributable to lead time bias; earlier diagnosis 
while investigating early decompensation or more severe 
portal hypertension. The latter was reflected in our cases 
by decreased liver size, lower platelet count, and larger 
varices. However, there was no difference in Child–Pugh 
score because this scoring system does not take into account 
the above factors. This may also explain why there was no 
difference in Okuda staging, which depends on the tumor 
size and three measures of the severity of cirrhosis (the 
amount of ascites and the serum albumin and bilirubin 
levels) included in the Child–Pugh scoring. There was also 
no difference in the BCLC staging, which is based on the 
extent of the primary lesion, performance status, vascular 
invasion, as well as Child class. The patient-centered 
approach in this system is more appropriate to segregate 
good surgical candidates for resection or radical therapy 
from those requiring palliative care while our patients in 
both groups presented late.
Our patients did not originate from a surveillance program, 
and diagnosis was made incidentally or for the presence 
of tumor-related symptoms. The patients were identified 
by the ICD coding system leading to the identification of 
hospitalized patients, with an advanced underlying liver 
disease as well as stage of the tumor. Most of our patients 
(except two in each group) had clinical cirrhosis. The 
diagnosis of liver cirrhosis was made by radiologic and clinical 
evaluation and biopsies were not done. This may influence 
the characterization of the tumor. However, in both groups 
cirrhosis stage was equally distributed. The possibility of 
early cirrhosis in four cases (two in each group) who did not 
have clinical cirrhosis cannot be ruled out.
The main strength of this paper is the large number of 
patients with HDV/HBV hepatocellular carcinoma evaluated. 
The diagnosis of HDV coinfection was made by measuring 
serum HDV antibodies and HDV RNA was not done. 
Considering this data it is not possible to determine if our 
patients were having an active form of hepatitis D at the 
time of presentation. Data concerning the serum levels of 
HBV-DNA and the status of HBe antigen and antibody was 
also not available in all cases. The patients were identified 
by the ICD coding system leading to the identification of 
hospitalized patients, with a severe underlying liver disease 
(high prevalence of Child–Pugh C patients), which may 
influence the characterization of the tumor. These are 
patients with really advanced tumors (small number of 
Okuda I patients in both groups). However, it is not possible 
to perform a case control prospective study as it would take 
years to get sufficient number of cases HDV-positive HCC 
cases. However, our findings may be confirmed in a large 
prospective multicenter study.
In summary, we have tried to identify some differences in the 
presentation of HCC in hepatitis D versus hepatitis B. More 
HDV patients have decreased liver size and indirect evidence 
of more severe portal hypertension and earlier TNM stage 
compared with HBV monoinfection. Multifocal tumors are 
more common in hepatitis B. These facts may indicate that 
HDV infection possibly causes HCC indirectly by inducing 
inflammation and cirrhosis.
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